|International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma|
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
|Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors|
A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ...
J Clin Oncol 23 (34), 8580-7, 2005
|Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders|
AV Jones, S Kreil, K Zoi, K Waghorn, C Curtis, L Zhang, J Score, R Seear, ...
Blood 106 (6), 2162-2168, 2005
|Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study|
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149, 2012
|International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma|
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
|Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid|
MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ...
Annals of Oncology 20 (1), 117-120, 2008
|Soluble receptor activator of nuclear factor ęB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index|
E Terpos, R Szydlo, JF Apperley, E Hatjiharissi, M Politou, J Meletis, ...
Blood 102 (3), 1064-1069, 2003
|Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid|
MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, ...
haematologica 91 (7), 968-971, 2006
|Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group|
MA Dimopoulos, E Terpos, A Chanan-Khan, N Leung, H Ludwig, ...
Journal of clinical oncology 28 (33), 4976-4984, 2010
|Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients|
K Zervas, E Verrou, Z Teleioudis, K Vahtsevanos, A Banti, D Mihou, ...
British journal of haematology 134 (6), 620-623, 2006
|Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report|
A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ...
Blood 125 (13), 2068-2074, 2015
|The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)|
E Voskaridou, D Christoulas, A Bilalis, E Plata, K Varvagiannis, ...
Blood 115 (12), 2354-2363, 2010
|Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)|
A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ...
Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011
|International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma|
M Dimopoulos, E Terpos, RL Comenzo, P Tosi, M Beksac, O Sezer, ...
Leukemia 23 (9), 1545, 2009
|Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid|
A Lipton, R Cook, F Saad, P Major, P Garnero, E Terpos, JE Brown, ...
Cancer 113 (1), 193-201, 2008
|International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease|
E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ...
Journal of clinical oncology 31 (18), 2347, 2013
|Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
P Moreau, J San Miguel, P Sonneveld, MV Mateos, E Zamagni, ...
Annals of Oncology 28 (suppl_4), iv52-iv61, 2017
|Myeloma bone disease: pathophysiology and management|
E Terpos, MA Dimopoulos
Annals of oncology 16 (8), 1223-1231, 2005
|The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network|
E Terpos, O Sezer, PI Croucher, R García-Sanz, M Boccadoro, ...
Annals of Oncology 20 (8), 1303-1317, 2009
|Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide|
MA Dimopoulos, A Anagnostopoulos, MC Kyrtsonis, K Zervas, C Tsatalas, ...
Journal of Clinical Oncology 25 (22), 3344-3349, 2007